Caladrius Biosciences is a clinical-stage biopharmaceutical company focused on the development of cellular therapies designed to reverse cardiovascular disease. Co.'s product candidates include three developmental treatments for ischemic diseases: CLBS12, eligible for early conditional approval in Japan for the treatment of critical limb ischemia ; CLBS16, in a clinical trial in the United States for the treatment of coronary microvascular dysfunction; and CLBS14, a Regenerative Medicine Advanced Therapy designated therapy for which it has finalized with the United States Food and Drug Administration a protocol for a confirmatory trial in subjects with no-option refractory disabling angina. The CLBS stock yearly return is shown above.
The yearly return on the CLBS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CLBS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|